Jul. 12 at 8:33 PM
$CLRB is primed to repeat the massive retail momentum we’ve seen in other biotechs—but with real data backing it.
Cellectar's Phase 2b CLOVER WaM data is already out, showing an elite 61.8% response rate in rare blood cancer.
The Catalyst Roadmap:
2026: CMA filing in Europe.
Late 2026: Phase 3 confirmatory study starts.
Early 2027: U.S. NDA submission for accelerated approval.
Backed by
$140M in milestone funding, the runway is secure. Institutions already in! Wall Street consensus rates it a "Strong Buy" with an average price target of
$14. A potential first-in-class, solo therapy for a major unmet need. 💪💪💪💪🚀🚀🚀🚀
